Related Experiment Video

Updated: Feb 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K

Pharmacotherapy for obesity management-Emphasizing the role of GLP-1 receptor agonist-based therapeutics

Bruce A Warden1, Paul Barton Duell2, John D Bucheit3

  • 1Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA (Drs Warden, Duell, and Purnell); General Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA (Dr Warden).

Journal of Clinical Lipidology
|February 18, 2026
PubMed
Abstract

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective obesity medications. These treatments offer disease-modifying outcomes and can help manage obesity and its complications.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Obesity is a complex chronic disease with increasing prevalence and significant health risks.
  • Historically, obesity treatments beyond lifestyle changes faced underutilization and stigma.
  • Effective management requires a multimodal approach including lifestyle, pharmacotherapy, and surgery.

Purpose of the Study:

  • To review the use of obesity medications (OM) in adults.
  • To focus on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonists.
  • To examine patient selection, treatment initiation, titration, benefits, risks, and cost.

Main Methods:

  • Review of current literature on obesity pharmacotherapy.
  • Emphasis on GLP-1 RA and GLP-1 RA/GIP dual receptor agonists.
  • Analysis of clinical practice guidelines and emerging evidence.

Main Results:

  • GLP-1 RAs represent a highly effective pharmacotherapy for obesity.
  • These agents demonstrate favorable safety and tolerability profiles.
  • Significant disease-modifying outcomes are associated with GLP-1 RA use.

Conclusions:

  • GLP-1 RAs are a valuable tool in managing obesity and its complications.
  • These medications can help mitigate the rising rates of obesity and related health issues.
  • Further research and access considerations are important for widespread adoption.
Keywords:
AdiposityGlucagon-like peptide-1 receptor agonistsObesity managementObesity medicationPharmacotherapy

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K
Self-Administration of Drugs in Mouse Models of Feeding and Obesity03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

5.2K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
302
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
702
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
715
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
752